Eduardo Rodriguez, MD
Internal Medicine · New Orleans, LANPI 1053363515
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,939 of the $4,622 with a category attached, or 85.2%. It is spread thinly across 34 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,190 and has fallen 56.3% since, to $957 in 2025.
Across 177 payments — averaging $26.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- AstraZeneca$769
- Novo Nordisk$386
- Bayer$327
- Amgen$254
- Akebia Therapeutics Inc$175
- plus $2K from 28 others
Across 90 payments — averaging $1812.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$105K
- Akebia Therapeutics Inc$44K
- Gilead$14K
What the payments were for
- Travel & lodging$65814%
- Food & beverage$3,93985%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $1,007 |
| AstraZeneca | 35 | $769 |
| Novo Nordisk | 19 | $386 |
| Bayer | 14 | $327 |
| Amgen(2 entities) | 16 | $254 |
| Akebia Therapeutics Inc | 8 | $175 |
| Boehringer Ingelheim | 9 | $162 |
| Idorsia Pharmaceuticals US Inc | 2 | $140 |
| Pfizer | 6 | $112 |
| Otsuka America Pharmaceutical, Inc. | 6 | $105 |
| Lilly USA, LLC | 6 | $101 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $100 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $100 |
| Calliditas Therapeutics US Inc. | 4 | $96 |
| Sanofi-aventis U.S. LLC | 5 | $94 |
| Abbott | 4 | $87 |
| Esperion Therapeutics, Inc. | 4 | $79 |
| Merck | 6 | $79 |
| Xeris Pharmaceuticals, Inc. | 2 | $47 |
| Ultragenyx Pharmaceutical Inc. | 2 | $47 |
| Corcept Therapeutics | 2 | $45 |
| Shire North American Group Inc | 3 | $43 |
| AbbVie | 2 | $32 |
| Seqirus USA Inc | 2 | $29 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $28 |
| Vifor Pharma, Inc. | 2 | $27 |
| Sanofi | 1 | $26 |
| Ardelyx, Inc. | 1 | $25 |
| Exact Sciences | 1 | $21 |
| Aurinia Pharma U.S., Inc. | 1 | $21 |
| Ascensia Diabetes Care US Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Baxter Healthcare | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,622 in reported general payments places this provider in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 91 | $109,311 |
| JardianceEmpagliflozin | 79 | $96,963 |
| JanuviaSitagliptin Phosphate | 53 | $58,086 |
| TrulicityDulaglutide | 24 | $35,088 |
| FarxigaDapagliflozin Propanediol | 23 | $24,453 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $12,437 |
| NexletolBempedoic Acid | 15 | $11,457 |
| MyrbetriqMirabegron | 13 | $10,488 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $10,343 |
| SynjardyEmpagliflozin/Metformin Hcl | 11 | $6,928 |
| Cinacalcet Hcl | 23 | $6,861 |
| Irbesartan | 417 | $6,393 |
| Repatha SureclickEvolocumab | 11 | $5,976 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $5,081 |
| Sevelamer Carbonate | 28 | $4,987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $112 | $109,31191 claims |
| Boehringer IngelheimJardiance, Synjardy | $162 | $103,89190 claims |
| MerckJanuvia | $79 | $58,08653 claims |
| Lilly USA, LLCTrulicity | $101 | $35,08824 claims |
| AstraZenecaFarxiga, Symbicort | $769 | $29,53442 claims |
| Esperion Therapeutics, Inc.Nexletol | $79 | $11,45715 claims |
| AbbVieSynthroid | $32 | $1,16815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in New Orleans
- Steven DeitelzweigNew Orleans$939K
- Daniel EnglertNew Orleans$74K
- Jordan GrahamNew Orleans$25K
- Pavan ChavaNew Orleans$24K
- Susan KaramNew Orleans$22K
- Arti ThanguduNew Orleans$20K
- David BrownNew Orleans$17K
- Peter PantlinNew Orleans$13K
- Genevieve MarongeNew Orleans$12K
- Samiullah ArshadNew Orleans$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.